에 대한 최신 뉴스 AbbVie (NYSE:ABBV) 주식

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Large Cap

News

Movers

ABBV

CACI

LDOS

MNDY

MPWR

MRNA

NVDA

PCVX

SMCI

XPEV

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 모놀리식 파워 시스템즈(NASDAQ:MPWR)의 주식은 24.68% 하락했다. 이는 엣지워터 리서치(Edgewater Research)의 분석 보고서에 따라 모놀리식의 엔비디아(NASDAQ:NVDA) 블랙웰(Blackwell) GPU에 대한 할당이 전력 관리 IC의 성능 문제로 위험에 처해 있다고 밝힌 후 발생한 일이다.

슈퍼 마이크로, 모더나 및 샤오펑은 지난주 최악의 성과를 보인 10개 대형주 중 일부 (11월 11일-15일)

Trading Ideas

AVGO

CIVI

DINO

GTLS

MUSA

SCCO

SHEL

TSLA

WFRD

바이킹 펀드 매니지먼트(Viking Fund Management)의 최근 13F 공시를 보면, 2024년 대선을 앞두고 일부 석유 기업 주식을 매도하는 등 3분기에 어떤 회사를 사고 팔았는지 확인할 수 있다. 13F 공시를 통해 보고한 포지션은 다음과 같다.

바이킹 펀드: 3분기에 대형 석유주 매각, 테슬라 포지션 절반으로 축소, 브로드컴 추가 매입

Equities

Previews

Tech

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GATX

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

AbbVie Inc

WIIM

AbbVie shares are trading higher after Leerink Partners upgraded the stock from Market Perform to Outperform and announced a price target of $206.

Analyst Ratings

CSCO

On CNBC, Jim Lebenthal Announced Bought More AbbVie; Bought More Cisco Systems

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584847d9ee7bf6000154d223/deane-dray">RBC Capital analyst Deane Dray</a> upgraded the rating for Flowserve Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) from Sector Perform to Outperform and announced a $69 price target. Flowserve shares closed at $60.05 on Thursday. See how other analysts view this stock.</li>
<li>Keybanc analyst Jeffrey Hammond upgraded RBC Bearings Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) from Sector Weight to Overweight and announced a $375 price target. RBC Bearings shares closed at $324.45 on Thursday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird analyst Shrenik Kothari upgraded the rating for Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) from Neutral to Outperform and raised the price target from $95 to $135. Elastic shares closed at $94.13 on Thursday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners analyst David Risinger upgraded the rating for AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from Market Perform to Outperform and announced a $206 price target. AbbVie shares closed at $171.73 on Thursday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Seaport Global analyst Glenn Chin upgraded Sonic Automotive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) from Neutral to Buy and announced a $74 price target. Sonic Automotive shares closed at $63.20 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ESTC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="559" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-1024x559.png" alt="" class="wp-image-660959" style="width:657px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-1024x559.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245.png 1205w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november"> </a>
<ul>
<li><a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

ESTC

This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Leerink Partners analyst David Risinger upgrades AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from Market Perform to Outperform and announces $206 price target.

Price Target

Leerink Partners Upgrades AbbVie to Outperform, Announces $206 Price Target

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie.
Looking at options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $1,433,900 and 5, calls, for a total amount of $514,031.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $190.0 for AbbVie over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $150.0 to $190.0 in the last 30 days. 
<h3>AbbVie Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732125634_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.06</td>
<td>$1.31</td>
<td>$1.38</td>
<td>$160.00</td>
<td>$1.2M</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$21.6</td>
<td>$21.55</td>
<td>$21.6</td>
<td>$150.00</td>
<td>$254.8K</td>
<td>14</td>
<td>118</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.4</td>
<td>$1.36</td>
<td>$1.4</td>
<td>$160.00</td>
<td>$145.9K</td>
<td>1.8K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.52</td>
<td>$190.00</td>
<td>$130.6K</td>
<td>207</td>
<td>380</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.1</td>
<td>$7.05</td>
<td>$7.05</td>
<td>$165.00</td>
<td>$69.7K</td>
<td>4.1K</td>
<td>116</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>Trading volume stands at 1,463,877, with ABBV's price up by 0.16%, positioned at $166.84.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 72 days.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $215.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $231. 
&#x2A; In a cautious move, an analyst from Wolfe Research downgraded its rating to Outperform, setting a price target of $205. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on AbbVie with a target price of $200. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $215. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on AbbVie with a target price of $224. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Unpacking the Latest Options Trading Trends in AbbVie

<ul>
<li>ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer</li>
<li>ELAHERE represents the first treatment to demonstrate an overall survival benefit in a Phase 3 trial in platinum-resistant ovarian cancer compared with chemotherapy</li>
<li>VENTANA FOLR1 (FOLR1-2.1)&nbsp;RxDx Assay, the companion diagnostic to identify ovarian cancer patients eligible for ELAHERE, also receives CE Mark</li>
</ul>

AbbVie Secures European Commission Approval For ELAHERE, First Novel Therapy For Platinum-Resistant Ovarian Cancer

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Monolithic Power Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) lost 24.68% last week as it was hit by an Edgewater Research analyst report that stated Monolithic's allocation to Nvidia's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Blackwell GPUs is in jeopardy due to performance problems with its Power Management ICs.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock tumbled 24.23% after the company recently announced it could not file its quarterly report for the period ending <a href="https://www.benzinga.com//node/41938588" target="_blank" rel="noreferrer noopener">September 30, 2024, on time</a>.</li>
<li>Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock fell 21.31% last week amid <a href="https://www.benzinga.com//node/42013119" target="_blank" rel="noreferrer noopener">pressure on vaccine stocks</a> after President-elect Donald Trump nominated Robert F. Kennedy Jr. to lead the HHS.</li>
<li>Leidos Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) shares dived 19.04%, probably because President-elect Trump made federal appointments during his transition period. Investors may evaluate the impact of possible cuts from the "<a href="https://www.benzinga.com//node/42013424" target="_blank" rel="noreferrer noopener">Department of Government Efficiency."</a></li>
<li>Monday.Com Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) stock fell 18.94% last week <a href="https://www.benzinga.com//node/41877454" target="_blank" rel="noreferrer noopener">despite the company reporting</a> a Q3 beat and raising its annual outlook.</li>
<li>Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) stock fell 18.60% last week amid <a href="https://www.benzinga.com//node/42013119" target="_blank" rel="noreferrer noopener">pressure on vaccine stocks</a> after President-elect Donald Trump nominated Robert F. Kennedy Jr. to lead the HHS.</li>
<li>Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) shares plummeted 18.59%.</li>
<li>AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock declined 17.30% last week after it announced that its Phase 2 EMPOWER trials did not <a href="https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges" target="_blank" rel="noreferrer noopener">meet their primary endpoints</a>.</li>
<li>CACI International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) shares decreased 17.16%.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares dipped 16.89%, reflecting a broader trend in U.S.-listed Chinese stocks. This market shift may be influenced by concerns surrounding President-elect Trump's administration picks, which could <a href="https://www.benzinga.com//node/41946780" target="_blank" rel="noreferrer noopener">signal a tougher stance toward China</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/42026369/shopify-disney-and-coinbase-were-among-top-10-large-cap-gainers-last-week-november-11-15-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Shopify, Disney And Coinbase Were Among Top 10 Large Cap Gainers Last Week (November 11-15): Are The Others In Your Portfolio?</a></li>
</ul>
Image by Robert Way via Shutterstock

Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/11/14/final-trades-bitcoin-abbvie-and-baker-hughes.html">Halftime Report Final Trades</a>,&#8221; Jason Snipe of Odyssey Capital Advisors picked AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
On Monday, AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the <a href="https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio">placebo group at week 6</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Stephen L. Weiss of Short Hills Capital Partners named Bitcoin as his <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41998395/bitcoin-ethereum-dogecoin-take-a-u-turn-as-jerome-powells-statements-dampen-rate-cut-expectations-analytics-firm-explains-why-btc-bull-market-has-not-yet-ended">final trade</a>.
Bitcoin prices pulled back as Federal Reserve Chair Jerome Powell&#8217;s remarks poured cold water on rate cut optimism. Bitcoin surged past the key $91,000 level on Thursday.
Joshua Brown of Ritholtz Wealth Management named Baker Hughes Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>).
On Oct. 22, Baker Hughes reported quarterly earnings of 67 cents per share which beat the analyst consensus estimate of 61 cents per share. The company reported quarterly sales of $6.91 billion. It missed the analyst consensus estimate of $7.22 billion. 
On Thursday, Citigroup analyst Scott Gruber maintained Baker Hughes with a Buy and raised the price target from $42 to $50.
Price Action:
<ul>
<li>At the time of writing, Bitcoin prices fell around 1.5%</li>
<li>AbbVie shares fell by 0.4% to settle at $169.63 during Thursday's session.</li>
<li>Baker Hughes gained 0.3% to close at $43.18 during Thursday's session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades'

Wolfe Research analyst Alexandria Hammond initiates coverage on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Outperform rating and announces Price Target of $205.

Initiation

Wolfe Research Initiates Coverage On AbbVie with Outperform Rating, Announces Price Target of $205

A new 13F filing from Viking Fund Management reveals which companies the fund bought and sold in the third quarter, including exiting some oil companies ahead of the 2024 election.
Third Quarter Exits: Viking Fund Management sold out of eight stocks completely in the third quarter, including positions in some of the largest oil companies.
Here are the positions exited, as <a href="https://13f.info/13f/000116906924000080/compare/000116906924000006">reported </a>by 13finfo:
<ul>
<li>Marathon Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>)</li>
<li>Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>)</li>
<li>SM Energy Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>)</li>
<li>Southern Copper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>)</li>
<li>Sociedad Quimica y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>)</li>
<li>Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>)</li>
<li>Sanofi SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NYSE">SNY</a>)</li>
<li>Cactus Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>)</li>
</ul>
Third Quarter New Positions: The following were the new stocks added to the fund in the third quarter, ranked in size by the dollar value at the end of the quarter.
<ul>
<li>Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>)</li>
<li>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>)</li>
<li>HF Sinclair Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>)</li>
<li>Weatherford International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>)</li>
<li>NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</li>
<li>Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)</li>
<li>Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>)</li>
<li>Vistra Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>)</li>
<li>United Microelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>)</li>
<li>Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>)</li>
<li>Portland General Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>)</li>
<li>Restaurant Brands International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>)</li>
<li>Nutrien (NTR.TO – Canada)</li>
</ul>
 Big Moves: The fund made several changes to its existing positions alongside the new positions and exited positions.
Here are the biggest additions in the quarter to existing stakes:
<ul>
<li>Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>): +16,900%</li>
<li>Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>): +882%</li>
<li>LyondellBassell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>): +400%</li>
<li>Rio Tinto PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>): +386%</li>
<li>Dow Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>): +200%</li>
</ul>
Here are the biggest position cuts during the quarter to existing stakes:
<ul>
<li>Texas Pacific Land (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>): -60%</li>
<li>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): -50%</li>
<li>Haliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>): -40%</li>
<li>ExxonMobil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>): -36%</li>
<li>Ovintiv (OVV.TO – Canada): -33%</li>
</ul>
Why It's Important: At the end of the quarter, these are the fund's largest positions ranked by dollar value and the percentage they make up of the fund:
<ul>
<li>Broadcom: $27.96 million, 4.5%</li>
<li>AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>): $24.88 million, 4.0%</li>
<li>NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): $22.65 million, 3.7%</li>
<li>Entergy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): $16.27 million, 2.6%</li>
<li>BlackRock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>): $14.24 million, 2.3%</li>
</ul>
The fund added significantly to its position in Broadcom, which remains the largest holding.
The quarter saw the sale of several oil stocks, but the fund opened new positions in several energy names in the quarter.
Photo: Shutterstock

Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie.
Looking at options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $363,304 and 9, calls, for a total amount of $346,984.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $150.0 and $185.0 for AbbVie, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for AbbVie options trades today is 3223.64 with a total volume of 4,480.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for AbbVie's big money trades within a strike price range of $150.0 to $185.0 over the last 30 days.
<h3>AbbVie Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731519926_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.98</td>
<td>$0.89</td>
<td>$0.98</td>
<td>$155.00</td>
<td>$115.8K</td>
<td>3.2K</td>
<td>1.3K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$17.3</td>
<td>$17.15</td>
<td>$17.15</td>
<td>$175.00</td>
<td>$102.9K</td>
<td>686</td>
<td>63</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$12.95</td>
<td>$11.9</td>
<td>$12.3</td>
<td>$160.00</td>
<td>$61.5K</td>
<td>1</td>
<td>50</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/13/24</td>
<td>$12.7</td>
<td>$11.2</td>
<td>$12.0</td>
<td>$160.00</td>
<td>$60.0K</td>
<td>1</td>
<td>100</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.98</td>
<td>$2.82</td>
<td>$2.98</td>
<td>$180.00</td>
<td>$48.5K</td>
<td>8.1K</td>
<td>174</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,130,867, with ABBV's price down by -0.09%, positioned at $170.93.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 79 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Smart Money Is Betting Big In ABBV Options

JP Morgan analyst Chris Schott maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight and lowers the price target from $210 to $200.

JP Morgan Maintains Overweight on AbbVie, Lowers Price Target to $200

Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and lowers the price target from $226 to $215.

Citigroup Maintains Buy on AbbVie, Lowers Price Target to $215

On Monday,&nbsp;AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappreciated" rel="noreferrer noopener">two Phase 2 trials</a>.
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.
Truist says due to the failure, Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Cobenfy (xanomeline and trospium chloride, KarXT) is poised to have less commercial competition.
The analyst also adds that the update will likely raise questions about strategy in neuroscience for AbbVie, which was highlighted during their <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41626490/abbvie-tops-q3-expectations-as-skyrizi-rinvoq-drive-growth" rel="noreferrer noopener">third-quarter earnings call</a>.
The analyst, with a Buy rating and $215 price target, is still positive on AbbVie&#8217;s growth prospects particularly from their immunology I&amp;I franchise.
Emraclidine was part of AbbVie&#8217;s acquisition of Cerevel last year, which also included Tavapadon, which recently reported positive Phase 3 results in Parkinson&#8217;s disease.
The trial met its primary endpoint – patients treated with tavapadon in both dose groups experienced a statistically significant reduction (improvement) from baseline compared to placebo (placebo: +1.8; 5 mg: -9.7; 15 mg: -10.2 versus placebo) in the Movement Disorder Society – Unified Parkinson&#8217;s Disease Rating Scale (MDS-UPDRS) Parts II and III <a href="https://www.benzinga.com/general/biotech/24/09/41050209/abbvie-says-pivotal-trial-for-parkinsons-candidate-meets-its-primary-goal-in-patients-with-early-" target="_blank" rel="noreferrer noopener">combined score at week 26</a>.
Also Read: <a href="https://www.benzinga.com//node/41884798">AbbVie&#8217;s Emraclidine For Schizophrenia &#8216;Surprisingly Disappoints,&#8217; Analyst Says Pipeline Is Underappreciated</a>
BMO Capital Markets writes, &#8220;AbbVie core I&amp;I thesis intact, but this one stings.&#8221;
The analyst has lowered the <a target="_blank" href="https://www.benzinga.com/quote/ABBV/analyst-ratings" rel="noreferrer noopener">price target from $228</a> to $208 and maintains the Outperform rating, citing confidence in the immunology portfolio.
BMO analyst writes that While Neurocrine Biosciences Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) mixed phase 2 data from NBI-1117568 <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40632561/neurocrine-biosciences-lower-dose-data-puts-its-schizophrenia-candidate-in-the-game" rel="noreferrer noopener">showed some efficacy</a>, there was absolutely no benefit in these trials. Bristol&#8217;s Cobenfy is now poised to dominate the schizophrenia market, the analyst adds.
BMO has reduced the probability of success for emraclidine to 0%, which was previously estimated to reach a potential $3.9 billion in global unadjusted peak sales in the Schizophrenia indication.
Price Action: ABBV stock is down 0.84% at $172.96 at last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41913107">Bristol-Myers Squibb&#8217;s $14 Billion Potential &#8211; Analyst Upgrades Stock</a></li>
</ul>

Analyst Color

Biotech

Health Care

Reiteration

General

NBIX

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio

Leerink Partners has upgraded Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy (a schizophrenia drug) and milvexian (anticoagulant).
The analyst expects upward pressure on Cobenfy (KarXT) and milvexian consensus expectations to drive stock outperformance from current levels.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a>
Leerink has upgraded from Market Perform to Outperform, with a price target of $73, <a target="_blank" href="https://www.benzinga.com/quote/BMY/analyst-ratings" rel="noreferrer noopener">up from the previous $55</a>, and adds that Bristol-Myers stock trades a substantial discount to the Diversified Biopharmaceutical median due to constrained EPS growth through 2029.
But the U.S. pharma giant&#8217;s exposure to loss of exclusivity (LOE) pressures diminishes in 2030+ relative to peers.
On Monday,&nbsp;AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock fell after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappreciated" rel="noreferrer noopener">two Phase 2 trials</a>.
With AbbVie&#8217;s emraclidine Phase 2 trial failures, Leerink no longer anticipates that a competing product will launch in 2026, thus boosting long-term Cobenfy projections, including 2030E sales from $4.2 billion to $5.7 billion.
&#8220;Cobenfy appears likely to be a pipeline within a product, with limited competitive threats from stand-alone M4 candidates,&#8221; Leerink analyst writes.
Leerink analyst estimates the potential for peak Cobenfy sales of over $10 billion if it succeeds in additional indications since Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zyprexa generated $5 billion in peak revenue in 2010 at much lower prices.
The analyst has also increased <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35878620/analyst-assess-implications-of-bristol-myers-investigational-blood-thinner-post-bay" rel="noreferrer noopener">milvexian sales projections</a>, with 2030E sales from $3.1 billion to $3.9 billion.
&#8220;We see the potential for milvexian peak sales to be above our 2025E Eliquis sales estimate of $14.4 billion if it delivers a superior benefit-risk profile in its atrial fibrillation Phase 3 in early 2027.&#8221;
Price Action: BMY stock is down 0.74% at $59.37 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/41910770/why-medical-device-firm-nevro-stock-is-trading-higher-on-tuesday" target="_blank" rel="noreferrer noopener">Why Medical Device Firm Nevro Stock Is Trading Higher On Tuesday</a></li>
</ul>
Courtesy of Bristol Myers Squibb

Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock

BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Outperform and lowers the price target from $228 to $208.

BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $208

Throughout the last three months, 14 analysts have evaluated AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $213.64, along with a high estimate of $231.00 and a low estimate of $195.00. Marking an increase of 5.76%, the current average surpasses the previous average price target of $202.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731420044_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive AbbVie is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$224.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$221.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Navin Jacob</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$231.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Andrew Baum</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$203.00</td>
<td>-</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Navin Jacob</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$212.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Steve Scala</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$209.00</td>
<td>$196.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AbbVie. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AbbVie compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for AbbVie's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of AbbVie's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ABBV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AbbVie analyst ratings.</a>
<h2>About AbbVie</h2>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>AbbVie: Delving into Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, AbbVie showcased positive performance, achieving a revenue growth rate of 3.83% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.73%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AbbVie's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 24.22%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): AbbVie's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.09%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 11.78, AbbVie faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 14 Analyst Ratings For AbbVie

Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight and lowers the price target from $231 to $224.

Morgan Stanley Maintains Overweight on AbbVie, Lowers Price Target to $224

<h3>Gainers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock rose 175.6% to $0.19 during Monday's pre-market session. The market value of their outstanding shares is at $28.9 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 27.07% to $2.3. The company's market cap stands at $4.2 million. As per the press release, Q3 earnings came out today. </li>
<li>RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) shares increased by 22.7% to $89.0. The market value of their outstanding shares is at $6.5 billion. The company's, Q3 earnings came out today. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares increased by 21.95% to $1.0. The company's market cap stands at $3.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares increased by 21.28% to $4.33. The market value of their outstanding shares is at $171.6 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares increased by 19.37% to $4.93. The company's market cap stands at $1.7 billion. As per the news, the Q3 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares declined by 48.1% to $1.5 during Monday's pre-market session. The company's market cap stands at $52.3 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares decreased by 17.3% to $1.1. The company's market cap stands at $26.9 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 15.55% to $0.34. The market value of their outstanding shares is at $2.1 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 13.73% to $3.71. The company's market cap stands at $4.9 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock decreased by 10.68% to $178.2. The market value of their outstanding shares is at $314.6 billion. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares fell 8.46% to $2.6. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CERO

DWTX

FRES

NUWE

RAPT

RDNT

REVB

SNES

TIVC

VIGL

12 Health Care Stocks Moving In Monday's Pre-Market Session

Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) announced that its Phase 2 EMPOWER trials did not <a href="https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges">meet their primary endpoints</a>.
The Details: Abbvie announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia did not meet their primary endpoint. 
The trials failed to show a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6. While the clinical trials did not meet their primary endpoint, emraclidine was well-tolerated with a safety profile comparable to that observed in the Phase 1b trial. 
&#8220;While we are disappointed with the results, we are continuing to analyze the data to determine next steps,&#8221; said&nbsp;Roopal Thakkar, executive vice president, research and development, chief scientific officer, AbbVie. 
&#8220;We would like to extend our gratitude to the study participants and their loved ones as well as to our network of clinical investigative sites for their participation in these trials. We are confident that our innovative pipeline will continue to bring meaningful therapies to patients, and we remain committed to finding better treatments for people living with psychiatric and neurological disorders.&#8221;
Related Link: <a href="https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappreciated">AbbVie&#8217;s Emraclidine For Schizophrenia &#8216;Surprisingly Disappoints,&#8217; Analyst Says Pipeline Is Underappreciated</a>
AbbVie is a large pharmaceutical company with a strong focus on immunology and neuroscience, while Bristol-Myers Squibb, though smaller, emphasizes therapies in oncology and cardiovascular disease. 
The U.S. Food and Drug Administration <a href="https://www.benzinga.com/general/biotech/24/09/40964682/bristol-myers-acquired-drug-karxt-poised-for-fda-approval-as-first-new-type-of-schizophrenia-trea">approved</a> Karuna Therapeutics&#8216; KarXT in September. It was the first schizophrenia drug to be approved since the 1950s. Bristol-Myers Squibb acquired Karuna Therapeutics for $330 per share in cash last year. 
BMY Price Action: At the time of publication, Bristol-Myers Squibb stock is up 11% at $60.12, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Courtesy of Bristol Myers Squibb

What's Going On With Bristol-Myers Squibb Shares Monday?

XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)

MoonLake Immunotherapeutics: A Somewhat Complicated Story

Optimism over global healthcare sector rises: Jefferies

Leerink upgraded AbbVie (ABBV) to Outperform from Market Perform with a $206 price target Published first on TheFly – the ultimate source for real-...

AbbVie upgraded to Outperform from Market Perform at Leerink

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

AbbVie upgraded, Baidu downgraded: Wall Street's top analyst calls

AbbVie upgraded to outperform by Leerink on recent sell-off

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-...

Trump Trade: Trump Media considers developing crypto payment service

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Amazon (AMZN) will invest an additiona...

Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz

AbbVie: Upgrading To 'Strong Buy' After Pullback

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

ALGT

ALHC

AMGN

AMZN

BIDU

BIIB

BITF

BNTX

CLOV

DXLG

GILD

GRAB

HALO

IESC

INTU

ISRG

MATW

MLTX

NVAX

PANW

PYPL

RDDT

REGN

REPL

ROKU

SHOO

SNYNF

SPGI

SQNXF

TEVA

TEVJF

TMDX

VWAGY

VWAPY

Screenshot 2024-11-13 at 11.54.41 PM

TNXP

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-05-14 at 6.27.53 PM

BRTX

CYNO

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Screenshot 2024-02-24 at 12.03.42 AM

AXSM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Earnings

Press Releases

AbbVie Reports Third-Quarter 2024 Financial Results

AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics

Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products

Comments

AbbVie

뉴스

에 대한 최신 뉴스 AbbVie (NYSE:ABBV) 주식

일요일, 11월 17, 2024

금요일, 11월 15, 2024

일요일, 7월 21, 2024

일요일, 7월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌